BioLineRx (BLRX) Total Liabilities (2021 - 2025)

BioLineRx has reported Total Liabilities over the past 5 years, most recently at $17.6 million for Q4 2025.

  • Quarterly results put Total Liabilities at $17.6 million for Q4 2025, down 30.99% from a year ago — trailing twelve months through Dec 2025 was $17.6 million (down 30.99% YoY), and the annual figure for FY2025 was $17.6 million, down 30.99%.
  • Total Liabilities for Q4 2025 was $17.6 million at BioLineRx, down from $25.4 million in the prior quarter.
  • Over the last five years, Total Liabilities for BLRX hit a ceiling of $50.7 million in Q4 2023 and a floor of $13.3 million in Q4 2021.
  • Median Total Liabilities over the past 5 years was $25.4 million (2024), compared with a mean of $26.5 million.
  • Biggest five-year swings in Total Liabilities: skyrocketed 98.5% in 2023 and later tumbled 49.81% in 2024.
  • BioLineRx's Total Liabilities stood at $13.3 million in 2021, then skyrocketed by 91.99% to $25.5 million in 2022, then skyrocketed by 98.5% to $50.7 million in 2023, then tumbled by 49.81% to $25.4 million in 2024, then plummeted by 30.99% to $17.6 million in 2025.
  • The last three reported values for Total Liabilities were $17.6 million (Q4 2025), $25.4 million (Q4 2024), and $50.7 million (Q4 2023) per Business Quant data.